Reducing hypertension in the elderly leads to a significant reduction in the incidence of stroke

June 27, 2002

(Prague, 27 June 2002) - Results from the SCOPE* study, examining the effect of antihypertensive treatment in elderly patients with mild hypertension, are presented for the first time today at the joint meeting of the International Society of Hypertension and the European Society of Hypertension, Prague.

These results show a significant 28% risk reduction (p=0.041) in non-fatal strokes in elderly people with mild hypertension - an often untreated group - when treated with the AT1-receptor blocker Atacand® (candesartan cilexetil), compared to the control group.

SCOPE also reported a non-significant trend to reduced risk (11% risk reduction; p= 0.19) in the Atacand® treatment group, of major CV events; defined as a combined endpoint of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. Lowering blood pressure was associated with maintained cognitive function, as measured by the MMSE (Mini Mental State Examination). There was no significant difference in the risk of heart attacks or cardiovascular death between treatment groups.

"SCOPE is a unique study," explains Professor Lennart Hansson, co-chair of the SCOPE Steering Committee. "It shows for the first time that treating mild hypertension in elderly people may have benefits on two counts. Reducing blood pressure with Atacand® offers real clinical benefits by significantly cutting people's risk of a non-fatal stroke."

"Importantly and perhaps contrary to current beliefs, SCOPE also shows that reducing blood pressure does not increase the risk of cognitive decline or the development of dementia in elderly people", continues Professor Hans Lithell. "These results have important implications for how we currently view and treat elderly patients with mild hypertension."

Interestingly, in addition to the positive effect on stroke, Atacand® also demonstrated a beneficial trend in onset of new diabetes (20% risk reduction ; p=0.083).

Hypertension, or high blood pressure, is the most common cardiovascular disorder. The World Health Organization estimates that there are nearly 691 million people throughout the world with hypertensive disease. The prevalence of high blood pressure (the number of people with the condition at any one time) is reported to be about 20 per cent of adult populations around the worldi. This figure is considerably higher in elderly people, and a prevalence of more than 50% has been reported.

SCOPE results are based on a randomised, double-blind, study in 15 countries to evaluate the effects of the AT1 -receptor blocker, Atacand® (candesartan cilexetil), on the clinical outcomes of 4,937 elderly patients (aged 70-89, average 76 years) with mild hypertension - typical of those found in everyday practice.

Atacand® has an established track record in blood pressure reduction with proven efficacy and placebo-like tolerability. Atacand® has accumulated some 4.2 million patient years of clinical experience. Previous studies have shown Atacand®'s efficacy in the treatment of hypertension - with studies showing superior efficacy to losartan, valsartan, hydrochlorothiazide and enalapril and equivalent efficacy to amlodipine. Atacand® also has placebo-like tolerability and is effective and well tolerated in elderly patients.

"We are pleased to have been able to sponsor such an innovative study," comments Dr Hamish Cameron, Vice-President and Head of Cardiovascular Therapy Area at AstraZeneca, the sole sponsors of SCOPE. "AstraZeneca is committed to cardiovascular medicine and are constantly striving to develop innovative therapeutic solutions and reduce the impact of cardiovascular disease."
* The Study on Cognition and Prognosis in the Elderly

Ketchum UK

Related Stroke Articles from Brightsurf:

Stroke alarm clock may streamline and accelerate time-sensitive acute stroke care
An interactive, digital alarm clock may speed emergency stroke care, starting at hospital arrival and through each step of the time-sensitive treatment process.

Stroke patients with COVID-19 have increased inflammation, stroke severity and death
Stroke patients who also have COVID-19 showed increased systemic inflammation, a more serious stroke severity and a much higher rate of death, compared to stroke patients who did not have COVID-19, according a retrospective, observational, cross-sectional study of 60 ischemic stroke patients admitted to UAB Hospital between late March and early May 2020.

'Time is vision' after a stroke
University of Rochester researchers studied stroke patients who experienced vision loss and found that the patients retained some visual abilities immediately after the stroke but these abilities diminished gradually and eventually disappeared permanently after approximately six months.

More stroke awareness, better eating habits may help reduce stroke risk for young adult African-Americans
Young African-Americans are experiencing higher rates of stroke because of health conditions such as high blood pressure, diabetes and obesity, yet their perception of their stroke risk is low.

How to help patients recover after a stroke
The existing approach to brain stimulation for rehabilitation after a stroke does not take into account the diversity of lesions and the individual characteristics of patients' brains.

Kids with headache after stroke might be at risk for another stroke
A new study has found a high incidence of headaches in pediatric stroke survivors and identified a possible association between post-stroke headache and stroke recurrence.

High stroke impact in low- and middle-income countries examined at 11th World Stroke Congress
Less wealthy countries struggle to meet greater need with far fewer resources.

Marijuana use might lead to higher risk of stroke, World Stroke Congress to be told
A five-year study of hospital statistics from the United States shows that the incidence of stroke has risen steadily among marijuana users even though the overall rate of stroke remained constant over the same period.

We need to talk about sexuality after stroke
Stroke survivors and their partners are not adequately supported to deal with changes to their relationships, self-identity, gender roles and intimacy following stroke, according to new research from the University of Sydney.

Standardized stroke protocol can ensure ELVO stroke patients are treated within 60 minutes
A new study shows that developing a standardized stroke protocol of having neurointerventional teams meet suspected emergent large vessel occlusion (ELVO) stroke patients upon their arrival at the hospital achieves a median door-to-recanalization time of less than 60 minutes.

Read More: Stroke News and Stroke Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to